Edition:
United States

Ampio Pharmaceuticals Inc (AMPE.A)

AMPE.A on American Stock Exchange

0.42USD
16 Aug 2017
Change (% chg)

-- (--)
Prev Close
$0.42
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
83,388
52-wk High
$1.11
52-wk Low
$0.40

AMPE.A

Chart for AMPE.A

About

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company's two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for... (more)
No analyst recommendations are available for AMPE.A.

Overall

Beta: 0.17
Market Cap(Mil.): $28.66
Shares Outstanding(Mil.): 68.23
Dividend: --
Yield (%): --

Financials

  AMPE.A Industry Sector
P/E (TTM): -- 79.56 32.84
EPS (TTM): -0.21 -- --
ROI: -100.21 2.86 14.86
ROE: -140.53 5.27 16.11

BRIEF-Ampio Pharmaceuticals entered into Addendum no. 7 to sponsored research agreement dated Sept 1, terminating research agreement effective July 5

* Ampio Pharmaceuticals - Entered into Addendum no. 7 to sponsored research agreement dated Sept. 1, terminating research agreement effective July 5 Source text: [http://bit.ly/2toXBVt] Further company coverage:

Jul 07 2017

BRIEF-Bruce Terker reports 6.58 pct passive stake in Ampio Pharmaceuticals - SEC filing

* Bruce E. Terker reports 6.58 percent passive stake in Ampio Pharmaceuticals Inc as of June 7, 2017 - SEC filing Source text: (http://bit.ly/2stcpDg) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Jun 14 2017

BRIEF-Ampio names Tom Chilcott as interim CFO

* Ampio announces appointment of interim chief financial officer

Jun 12 2017

BRIEF-Ampio Pharmaceuticals reports closing of registered direct offering

* Ampio Pharmaceuticals, Inc. announces closing of registered direct offering Source text for Eikon: Further company coverage:

Jun 07 2017

BRIEF-Ampio Pharmaceuticals announces pricing of registered direct offering

* Ampio Pharmaceuticals Inc announces pricing of registered direct offering

Jun 02 2017

BRIEF-Ampio Pharmaceuticals files for non-timely 10-Q

* Ampio Pharmaceuticals says intends to file form 10-Q as soon as practicable, but no later than May 15, 2017 Source text for Eikon: Further company coverage:

May 11 2017

BRIEF-Ampio Pharmaceuticals files for mixed shelf of up to $100 mln

* In addition, 5.0 million shares of co's common stock offered by the selling stockholder Source text (http://bit.ly/2okuxNM) Further company coverage:

Mar 31 2017

BRIEF-Ampio Pharmaceuticals amends warrant agreement

* Ampio Pharmaceuticals- entered into waiver, consent letter agreement with CVI Investments amending terms of warrants previously issued to CVI on Sept. 1, 2016

Mar 28 2017

BRIEF-Ampio pharmaceuticals provides corporate update

* Ampio pharmaceuticals - plans to advance all necessary biologic license application activities in parallel to expedite path to potential FDA approval

Mar 20 2017

BRIEF-Ampio receives guidance from the FDA

* Ampio receives guidance from the FDA and proposes a path for approval for single-injection ampion™ for the treatment of pain due to severe osteoarthritis of the knee

Feb 27 2017

Earnings vs. Estimates